课题基金 / 基金详情

IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS

IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
IDEC Y2B8 与 RITUXAN 在难治性低级别或滤泡 B 细胞非霍奇金淋巴瘤中的比较
批准号：
6303008
负责人：
MANSOOR N SALEH
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303008
关键词：
antibody antineoplastics clinical research human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neoplasm /cancer relapse /recurrence nonHodgkin's lymphoma radiotracer

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项CD20阳性非霍奇金淋巴瘤（低级别）复发或常规治疗后复发的一线单克隆抗体治疗的随机试验。将患者随机分配至Y902B8与C2B8组，以评价疗效。 到目前为止，我们已经治疗了4名患者。 Y2B8组1例，C2B8组3例。初步个体结局数据反映了个体治疗方案的预期应答。 这项研究已经积累了人口，等待分析。
英文摘要
This was a randomized trial of first line monoclonal antibody therapy of CD20 positive non-Hodgkin's lymphoma (low grade) following recurrence or relapse following conventional therapy. Patients are randomized to Y902B8 vs. C2B8 to evaluate efficacy. To date we have treated 4 patients. 1 on the Y2B8 arm and 3 on the C2B8 arm. Preliminary individual outcome data reflects the anticipated response to the individual treatment options. The study has accrued its population and awaits analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金